J Korean Cancer Assoc.  1998 Apr;30(2):350-356.

Results of CHOP-Bleo / CMED Alternating Chemotherapy for Aggressive Non - Hodgkin's Lymphoma

• Kim SJ
• Choi IK
• Oh SC
• Seo JH
• Kim BS
• Shin SW
• Kim YH
• Kim JS

Abstract

PURPOSE
To assess the efficacy and toxicity of a new protocol that consists of CHOP- Bleo alternated with a new regimen of Cyclophosphamide, methotrexate, etoposide, and dexamethasone(CMED) for aggressive Non-Hodgkin's Lymphoma(NHL).
PATIENTS AND METHODS
Between January 1991 and December 1996, forty-six patients with Ann Arbor stages II-IV aggressive NHL were treated with alternating cycles of CHOP-Bleo and CMED for a total of 12 cycles. All eligible patients were evaluated for response, disease-free survival, and overall survival.
RESULTS
Twenty-two patients(47.8%) achieved a complete response and overall response rate was 83.9%. The range of survival duration was 1-68+months and the median survival time was 42 months. Overall 3-year survival rate was 54%. The range of disease-free survival time was 6-63+months and 3-year disease-free survival rate was 61%. The most common hematologic toxicity was leukopenia and the incidence of severe leukopenia(<1,000/mm3) was 11%. And alopecia(84.8%) was the most common non-hematologic toxicity.
CONCLUSION
The results of CHOP-Bleo/CMED alternating chemotherapy for patients with aggressive Non-Hodgkin's Lymphoma is not superior to other results of previous studies. Therefore further study will be warranted to determine clinical effectiveness of alternating chemotherapy.

Keyword

Cyclophosphamide-adriamycin-vincristine-prednisone-bleomycin(CHO- Bleo); Cyclophosphamide-methotrexate-etoposide-dexamethasone(CMED); Altemating chemotherapy; Aggressive non-Hodgkin's lymphoma

MeSH Terms

Cyclophosphamide
Disease-Free Survival
Drug Therapy*
Etoposide
Hodgkin Disease*
Humans
Incidence
Leukopenia
Lymphoma, Non-Hodgkin
Methotrexate
Survival Rate
Cyclophosphamide
Etoposide
Methotrexate